- Datum16.12.2025
- Uhrzeit16:30 - 17:30 Uhr
- Veranstalter
stock3
Rezolute Inc. Registered Shares New DL -,001 Aktie
Verkaufen
Kaufen
Rezolute Inc. Registered Shares New DL -,001 Chart inkl. Chartanalyse
Charts analysieren
wie die Profis?
Nutze unser Profi-Charting-Tool für Deine eigenen Analysen
Chart analysieren
Rezolute Inc. Registered Shares New DL -,001 Realtime-Kurs
| Handelsplatz | Kurs | +/- (%) | +/- (abs) | Vortag | Zeit | Aktionen |
|---|---|---|---|---|---|---|
| L&S | VK | |||||
| Tradegate | VK | |||||
| LS Exchange | VK |
Passende Produkte
| WKN | Long/Short | KO | Hebel | Laufzeit | Bid | Ask |
|---|
Keine Ergebnisse gefunden
Wertentwicklung (Nasdaq)
28,57 %
Intraday
-82,73 %
1 Woche
-81,89 %
1 Monat
-63,27 %
Seit Jahresbeginn
-60,78 %
1 Jahr
16,88 %
3 Jahre
-90,86 %
5 Jahre
Passender Service zu Rezolute Inc. Registered Shares New DL -,001
Webinar zu Rezolute Inc. Registered Shares New DL -,001
Kursinformationen (Nasdaq)
- Tagestief / Hoch ($)-
- 52W-Tief / Hoch ($)1,070-11,457
- Jahrestief / Hoch ($)---
- Schlusskurs (Vortag)
- Eröffnungskurs
- Volumen Intraday
Wichtigste Eigenschaften
Dividenden von Rezolute Inc. Registered Shares New DL -,001
Keine Dividenden verfügbar
Termine von Rezolute Inc. Registered Shares New DL -,001
Keine aktuellen Termine
Beschreibung
Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, a selective and potent plasma kallikrein inhibitor, which is in Phase 1 clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.
